OpenEvidence vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
OpenEvidence hit $100M+ ARR in under a year serving 430K+ US physicians (40% of all US doctors) at $12B valuation ($700M raised); fastest-growing physician AI platform, founded 2022 Miami.
About
OpenEvidence is an AI clinical evidence platform founded in 2022 and headquartered in Miami, Florida. Built specifically for physicians, the platform applies large language models trained on peer-reviewed medical literature to deliver instant, evidence-backed answers to clinical questions at the point of care. Its founding mission is to democratize access to the best available medical evidence so that every physician can practice at the highest standard, regardless of institution or specialty.\n\nThe platform aggregates and synthesizes peer-reviewed studies, clinical guidelines, and drug databases, presenting structured answers with citations that meet physician-grade accuracy standards. Unlike general-purpose AI assistants, OpenEvidence is purpose-built for clinical workflows. It is free to use for physicians, with monetization routed through pharmaceutical and healthcare industry partners who value the platform's direct access to practicing clinicians.\n\nOpenEvidence has achieved remarkable traction, reaching over 430,000 US physicians — approximately 40% of the entire US physician population — making it the fastest-growing physician AI platform on record. The company crossed $100M ARR in under a year from launch and earned a $12 billion valuation on $700 million in total funding. This trajectory places OpenEvidence among the fastest-scaling healthcare AI companies globally and signals a structural shift toward AI-assisted clinical decision-making at the point of care.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.